Published in final edited form as:

Mol Cancer Res. 2015 July ; 13(7): 1059–1072. doi:10.1158/1541-7786.MCR-15-0068.

Dissecting the Dual Role of AMPK in Cancer: from Experimental to Human Studies

Giorgia Zadra^{1,2,*}, Julie L. Batista^{3,4,*}, and Massimo Loda^{1,2,5,6}

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA

²Department of Pathology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA

³Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA

⁴Channing Division of Network Medicine, Brigham and Women's Hospital/Harvard Medical School Boston, MA, USA

⁵The Broad Institute, Cambridge, MA, USA

⁶Division of Cancer Studies, King's College London, UK

Abstract

The precise role of 5'AMP-activated kinase (AMPK) in cancer and its potential as a therapeutic target is controversial. While it is well established that activation of this energy sensor inhibits the main anabolic processes that sustain cancer cell proliferation and growth, AMPK activation can confer on cancer cells the plasticity to survive under metabolic stress such as hypoxia and glucose deprivation, which are commonly observed in fast growing tumors. Thus, AMPK is referred to as both a “conditional” tumor suppressor and “contextual” oncogene. To add a further layer of complexity, AMPK activation in human cancer tissues and its correlation with tumor aggressiveness and progression appears to vary in different contexts. The current review discusses the different faces of this metabolic regulator, the therapeutic implications of its modulation and provides an overview of the most relevant data available on AMPK activation and AMPK activating drugs in human studies.

Keywords

AMPK; tumor suppressor; tumor promoter; cancer survivorship; and chemoprevention

Corresponding author: Massimo Loda, Department of Pathology, Dana-Farber Cancer Institute, 450 Longwood Avenue, D1536, Boston, MA 02115-5450. massimo_loda@dfci.harvard.edu Phone: (617) 632-4001, Fax: (617) 632-4005.

*These authors equally contribute to the Review

Conflicts of interest

The authors have no conflicts of interest to declare.

Introduction

5' AMP-activated kinase (AMPK) is a central metabolic sensor that stands at the crossroad between metabolic and signaling networks. In 2003, the discovery of the tumor suppressor liver kinase B1 (LKB1) as the major upstream kinase of AMPK established a link between an energy regulator and cancer pathogenesis, suggesting that the tumor suppressor functions of LKB1 could be mediated by AMPK (1–3). Since then, *in vitro* and *in vivo* studies have been conducted to dissect the role of AMPK in cancer initiation and progression, using AMPK modulating drugs. The functional consequences of AMPK activation in cancer appear to be much more complex than initially thought and AMPK can behave as both cancer “friend” or “foe” in a context-specific manner.

Drug-induced supra-physiological activation of AMPK reduces tumor growth *in vitro* and in pre-clinical models through the suppression of key biosynthetic pathways (reviewed in (4, 5)). However, physiological activation of AMPK in response to a broad range of stresses (e.g. hypoxia, glucose deprivation, and matrix detachment) provide cancer cells with the flexibility to adapt and survive metabolic stress (metabolic adaptation) (reviewed in (6)). Immunohistochemical evaluation of AMPK status in human tissues has revealed that the levels of AMPK activation are heterogeneous in different tumor types, while discordant data have been reported on the correlation between AMPK activation and tumor prognosis.

Here, we discuss the “two faces” of AMPK, the therapeutic benefit of AMPK modulators and we review the current data available on AMPK activation and AMPK activating drugs in human studies. Throughout the review, we will associate AMPK with both the terms “tumor promoter” and “tumor suppressor”. However, we do not intend to define AMPK as a classical *bona fide* tumor suppressor gene such as LKB1, which is mutated or deleted in several cancers, rather to emphasize the fact that AMPK activation may result in tumor growth inhibition, cell cycle arrest, and apoptosis of cancer cells in some tumor types/ contexts. Interrogating the cBioPortal data, the frequency of mutation/deletion in the genes codifying for AMPK catalytic subunits $\alpha 1$ (*PRKAA1*) and $\alpha 2$ (*PRKAA2*) ranges from 0.2–3.4% and from 0.2–10.3%, respectively (7).

AMPK: a unique metabolic “guardian” with pleiotropic downstream targets

AMPK is a heterotrimeric Ser/Thr kinase complex characterized by a catalytic α subunit and two regulatory subunits (β , γ), which exist in different isoforms making up to 12 different heterotrimers. The different subunits show tissue-specificity and may contribute to tumor cell growth and proliferation independently (8–10). The γ subunit contains four-tandem sequence repeats known as CBS repeats, which functions as four adenine nucleotide-binding domains. Site 2 is always unoccupied, site 4 is permanently bound by AMP, whereas sites 1 and 3 can be competitively bound by either AMP, or ADP, or ATP (11, 12).

AMPK functions as an energy sensor to restore energy homeostasis at cell and organismal levels in conditions of metabolic stress that reduce ATP levels either by inhibiting its production (e.g. hypoxia, glucose deprivation, and treatment with biguanides drugs or xenobiotics) or by accelerating its consumption (e.g. muscle contraction), resulting in increased ADP and AMP levels. For a detailed description of AMPK regulation, we refer

readers to other excellent reviews (13, 14). However, a brief description of the biochemical circuits regulating AMPK follows. The binding of ADP and/or AMP to the γ subunit both promotes phosphorylation by upstream kinases and inhibits dephosphorylation of the residue Thr172 within the activation loop of the catalytic domain, which is required for the full activity of the kinase. Furthermore, the binding of AMP (but not ADP) causes a further allosteric activation of the phosphorylated kinase. The two major upstream kinases responsible for AMPK activation are the tumor suppressor LKB1 and Ca²⁺/calmodulin-dependent protein kinase kinase 2 (CaMKK2). An activating role, still not well characterized, for the transforming growth factor beta-activated kinase 1 (TAK1) has also been described. LKB1 activates AMPK during energy stress, whereas CaMKK2 activity is induced by increased intracellular Ca²⁺ levels, regardless of the energy status of the cells (reviewed in (13)). However, CaMKK2 can compensate for the absence of LKB1 in mediating AMPK phosphorylation (15). In addition to AMP, ADP and Ca²⁺, recent studies have also identified reactive oxygen species (ROS) as additional upstream activators of AMPK, acting in an LKB1-independent manner (16) (Fig. 1). Once activated, AMPK maintains energy balance by switching off anabolic pathways that consume ATP and NADPH, while switching on catabolic pathways that generate ATP both by direct phosphorylation of metabolic enzymes, and through longer-term effects mediated by phosphorylation of transcription factors and co-activators (14). Thus AMPK can restrain cell growth by: (i) inhibiting protein synthesis [through direct phosphorylation of mammalian target of rapamycin complex 1 (mTORC1) signaling members tuberous sclerosis complex 2 (TSC2) and Raptor], (ii) blocking fatty acid (FA) and cholesterol biosynthesis [through direct phosphorylation of the enzymes acetyl-CoA carboxylase 1 (ACC1) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and inhibition of the lipogenic transcription factors sterol regulatory element-binding proteins (SREBPs) and carbohydrate-responsive element-binding protein (ChREBP)], required for new membrane formation in proliferating cells, (iii) inducing cell cycle arrest and apoptosis [through several mechanisms including stabilization of p53, regulation of the cyclin-dependent kinase inhibitors p21^{Waf1} and p27^{Cip1}, phosphorylation of the hippo signaling member angiomotin-like 1 (AMOTL1), an upstream inhibitor of Yes-associated protein (YAP) (13, 17, 18)], while promoting cell survival mechanisms during metabolic stress (19), as discussed below (Fig. 2).

Role of AMPK in cancer: pre-clinical studies

AMPK as a tumor suppressor

Since the role of LKB1 as tumor suppressor was well established, AMPK was primarily considered as a component of the LKB1-mediated tumor suppressor cascade and much less was known regarding its own independent role in cancer. This was due to the fact that most of the data were generated utilizing the AMPK activators AICAR and metformin, which also display AMPK-independent mechanisms or by experimental evidence in models of LKB1 inactivation, which affect an additional 12 AMPK-related downstream kinases, beyond AMPK. The role of the AMPK-related kinases is still not very well characterized, though they might themselves contribute to the tumor suppressive functions of LKB1, as well as have independent functions (20). Experiments of genetic ablation of AMPK, the use of direct AMPK activators, and detailed phosphorylation studies in different cancer models

have recently helped to address this issue. Faubert et al. have reported that the ubiquitous knockout (KO) of AMPK α 1, the only catalytic subunit expressed in B cells, accelerates the development of lymphomas in transgenic mice overexpressing c-Myc, suggesting that AMPK loss can cooperate with oncogenic drivers to promote tumorigenesis in a tissue-specific manner. The underpinning mechanism for AMPK tumor suppressor activity is the ability of the kinase to exert an “anti-Warburg” effect by downregulating hypoxia-inducible factor 1- α (HIF-1 α) and its downstream glycolytic genes, which conversely are upregulated in AMPK α 1 KO mice (21).

Aside from antagonizing the Warburg effect, AMPK has also been shown to exert its “metabolic” tumor-suppressor role by inhibiting unchecked mTORC1 activity and *de novo* lipogenesis, required both during G1/S and G2/M phases. We have recently observed increased *de novo* fatty acid (FA) synthesis concomitant to reduced AMPK activation and phosphorylation of its major target ACC1 (the rate-limiting enzyme for FA synthesis), prior to cytokinesis initiation. In this view, by inhibiting *de novo* FA synthesis and FA incorporation into membranes, activation of AMPK would prevent cells from completing mitosis, arresting them at a “lipogenic” G2/M checkpoint. This was indeed observed under direct supra-physiological activation of AMPK (22). Cell cycle arrest (via decreased fraction of cells in the S phase) and/or apoptosis, was previously confirmed using ACC1 and fatty acid synthase (FASN) siRNA to directly inhibit FA synthesis (23, 24).

AMPK also plays a direct metabolic-independent role in cell cycle regulation (25–27). A fine-tuned biphasic activation of AMPK has been shown to be required for proper mitotic progression (28). However, alteration of the dynamic spatial and temporal regulation of AMPK by either its sustained activation or depletion can result in microtubule misalignment, spindle misorientation, abnormal chromosome segregation followed by mitotic catastrophe and polyploidy (e.g. observed under metformin treatment) or mitotic delay (e.g. observed in AMPK-silenced cells) (27, 29). Thus, cell cycle arrest induced by persistent supra-physiological activation of AMPK could be ascribed to both the inhibition of *de novo* FA synthesis (metabolic role) as well as mitotic spindle assembly/chromosome segregation abnormalities (non-metabolic role). Recently, a role for the subunit AMPK α 1 in the direct regulation of cell cycle, independently of energy balance, has also emerged (30).

A third mechanism in favor of AMPK’s behavior as a “tumor suppressor” has been described by Shen et al., showing AMPK-dependent phosphorylation of the oncogene BRAF at Ser729. This phosphorylation prevents BRAF interaction with the scaffolding protein kinase suppressor of Ras 1 (KSR1), leading to the suppression of the oncogenic MEK-ERK signaling and consequent impairment of cell proliferation and cell cycle progression (31).

Furthermore, additional mechanisms of action to suppress tumor growth have been proposed. Chou et al. showed that AMPK knock down promotes “epithelial-mesenchymal transition” (EMT) in breast and prostate cancer cell lines by reducing the expression of forkhead box O3 (Foxo3a) and E-cadherin in conjunction with increased expression of vimentin, Y-box-binding protein-1 (YB-1), Snail, and the formation of F-actin stress fibers

(32). These results suggested that AMPK activation counteracts EMT, the process through which epithelial cells are thought to acquire cancer stem cell-like properties and gain the ability to breach basement membranes and metastasize to distant sites. DeRan et al. showed that AMPK activation induces phosphorylation of the hippo signaling component AMOTL1, which results in the cytoplasmic sequestration and inhibition of YAP and its targeted genes, involved in proliferation and survival. This mechanism was abolished when AMPK expression was silenced, suggesting that loss of AMPK activity may contribute to tumorigenesis through AMOTL1 destabilization, leading to hyperactivation of YAP (18). Finally, AMPK may be inactivated by its ubiquitination and degradation by the cancer-specific MAGE-A3/6-TRIM28 ubiquitin ligase. MAGE-A3 and MAGE-A6 proteins, normally expressed only in the male germline, are frequently re-activated in human cancers, they are necessary for cancer cell viability, and sufficient to induce cell transformation. Screening for targets of MAGE-A3/6-TRIM28 complex revealed that it ubiquitinates and degrades AMPK α 1, leading to inhibition of autophagy, activation of mTORC1 signaling, and hypersensitization to AMPK agonists, such as metformin. These findings elucidated a germline mechanism commonly hijacked in cancer to suppress AMPK (33).

Further evidence also supports the tumor suppressor role of AMPK in some tumor types and genetic contexts. First, protein kinase B (Akt), has been reported to induce AMPK phosphorylation at Ser485, reducing its activation by LKB1 (34). This might occur in tumors in which Akt is hyperactivated due to phosphatase and tensin homolog (PTEN) loss-of-function mutations, or activating mutations in phosphoinositide-3-kinase (PI3K). Second, AMPK activation is suppressed in melanoma cells carrying the most common BRAF mutation V600E, which induces a constitutively active downstream ERK. The lack of AMPK activity is due to ERK and ribosomal S6 kinase (RSK)-mediated phosphorylation of LKB1, which prevents its binding/activation of AMPK. These data suggested that suppression of LKB1/AMPK pathway might play an important role in BRAF V600E-driven tumorigenesis (35). Third, inhibition of AMPK has been observed in a PTEN-deficient model of thyroid cancer and in NSCLC cells expressing the mitochondrial heat shock protein 90 chaperone TRAP-1 (36). Fourth, in fumarate hydratase-deficient kidney tumors and cell lines from patients with hereditary leiomyomatosis renal cell cancer (HLRCC), which are characterized by a metabolic shift to aerobic glycolysis, AMPK levels are decreased. AMPK reduction leads to diminished expression of the DMT1 iron transporter, cytosolic iron deficiency, and activation of the iron regulatory proteins, IRP1 and IRP2, resulting in increased expression of HIF-1 α . Silencing of HIF-1 α or activation of AMPK diminishes invasive activities of the HLRCC cell line UOK262, indicating that overexpression of HIF-1 α and downregulation of AMPK contribute to the oncogenic growth of fumarate hydratase- deficient cells (37). Recently, a study from Rodriguez et al. showed that Cytochrome P450-1A1, constitutively expressed in the majority of breast cancer tumors, promotes breast cancer proliferation and survival, at least in part, through suppression of AMPK signaling (38). Finally, reduced expression of the catalytic α 2 subunit has been reported in some cases of hepatocellular carcinomas and it is associated with enhanced tumor cell growth in mouse xenografts (10).

Taken together, these results suggest that in specific genetic, metabolic, and signaling contexts, AMPK can exert a tumor suppressor role (Fig. 3).

AMPK as contextual tumor promoter

The ability to survive in conditions of metabolic stress, such as hypoxia/nutrient deprivation, or matrix detachment is fundamental to cancer cells. Several mechanisms by which the AMPK pathway supports this plasticity have been described. These include: (i) the induction of autophagy by AMPK-dependent phosphorylation of the unc-51-like kinases (ULK) (39), (ii) the promotion of FA oxidation (FAO) to generate ATP (40, 41), (iii) transcriptional changes induced by phosphorylation of the core histone H2B (42), (iv) the increase of intracellular NADPH levels through the activation of FAO/inhibition of FA synthesis to neutralize cytotoxic ROS (43) (Fig. 3). Intriguingly, while in nutrient-replete conditions, the AMPK energy-sensing pathway and the PI3K/Akt cascade converge on mTOR with opposing regulatory effects, under glucose depletion, both AMPK and Akt are activated and coordinately support cell survival (44). Thus, whereas the LKB1/AMPK pathway can act as a tumor suppressor through its ability to restrain tumor growth, it can also behave as “tumor promoter”, allowing tumor cells to be more resistant to metabolic stress, such as when tumor growth exceeds the capacity of its blood supply to deliver oxygen and nutrients (Fig. 4). Recent experimental evidence *in vitro*, using the direct AMPK activator A-769662, indeed supports this notion (45). AMPK activation can also promote tumor growth in specific tumor types and genetic contexts, even in nutrient-replete conditions.

Recent evidence showed the key role of AMPK in supporting tumor growth in aggressive breast and astrocytic tumors (46–49). Moreover, in contrast to the results obtained by Faubert et al in a lymphoma model (21), MYC has been shown to establish a dependence on AMPK-related kinase 5 (ARK5) to maintain metabolic homeostasis and cell survival. Depletion of ARK5 prolongs survival in MYC-driven mouse models of hepatocellular carcinoma, suggesting that targeting cellular energy homeostasis is a valid therapeutic strategy to eliminate tumor cells that express deregulated MYC (50).

The therapeutic benefit of AMPK modulators: the metformin paradox

The better understanding of the dichotomous role of AMPK in cancer has also brought about the careful re-evaluation of the use of AMPK modulators in cancer therapy. In this regard, the case of metformin is emblematic.

The interest in using AMPK activators began as evidence was accumulating for the anti-tumorigenic role of the LKB1/AMPK axis. The anti-proliferative and growth-suppressing effects of supra-physiological activation of AMPK have been shown *in vitro* and in pre-clinical models. Activation was achieved with natural compounds, the AMP mimetic drug AICAR as well as the biguanides metformin and phenformin, which inhibit complex I of the mitochondrial electron transport chain, leading to increased levels of intracellular ADP, AMP, and energy stress (reviewed in (4, 14, 51)) Metformin has received particular attention since it is a safe medication, used as first choice in the treatment of type II diabetes and has been associated with reduced cancer incidence in diabetic patients (52). Thus, it is currently being tested for cancer treatment/prevention in several clinical trials, as discussed below. However, ascribing metformin's anti-tumor properties *in vivo* to AMPK activation has been criticized since the major effect of the drug is the inhibition of hepatic gluconeogenesis, resulting in reduced circulating levels of glucose and insulin, two well-

known promoters of tumor cell proliferation. This is also valid for metformin's anti-tumor effects *in vitro*, where several AMPK-independent mechanisms have been described (45, 53–56). Moreover, the discovery of the so-called “biguanide paradox” has recently suggested that, in specific contexts, metformin-mediated suppression of tumor growth does not depend on AMPK activation but, rather, on its down-regulation. Because cells with a defective LKB1/AMPK pathway are less able to restore ATP levels in response to metabolic stress induced by metformin treatment, LKB1/AMPK-deficient cancer cells are more susceptible to cell death than their counterparts with a functional LKB1/AMPK axis (Fig. 5). Several *in vitro* and *in vivo* studies using metformin, phenformin, or other compounds that cause metabolic stress (AICAR, salicylate, and 2-deoxyglucose) have supported this mechanism (discussed in (57, 58)). In light of this, the use of biguanides may be most effective in combination with agents that inhibit, rather than activate, AMPK and, overall, these data suggest that the use of AMPK inhibitors rather than activators would preferentially trigger cancer cell death in the context of metabolic stress. Interestingly, the chemotherapeutic agent sunitinib has been shown to inhibit AMPK, suggesting that combinatorial treatment of sunitinib and metformin could be clinically relevant (59).

Novel direct AMPK activators have been developed to overcome the off-target effects of metformin and AICAR treatment. The direct activator A-769662 (which binds the $\beta 1$ subunit) delays tumor formation in PTEN null/LKB1 hypomorphic mice (60). The same compound has been shown to suppress the proliferation of breast, colon, and prostate cancer cells (61–63). A-769662 was however ineffective in models of glioma (56). OSU-53, a direct activator that binds the auto-inhibitory domain of AMPK, displays tumor growth inhibition *in vitro* and *in vivo* in triple-negative breast cancer models (64). The same group reported that AMPK activation by OSU-53 blocks “EMT” in breast and prostate cancer cells by activating Foxo3a, which results in the inhibition of invasive phenotypes *in vitro* and metastatic properties *in vivo* (32). Direct supra-physiological activation of AMPK in nutrient-replete conditions has been also shown to suppress prostate cancer cells growth, in association with mitotic arrest and apoptosis, and to potentiate the effect of anti-androgens *in vitro* (65). The inhibitory effect of AMPK activation on the androgen receptor (AR) axis at both transcriptional and post-translational levels was previously observed when a supra-physiological activation of AMPK was achieved by treatment with metformin or AICAR (66, 67). Finally, Compound 1, a novel AMPK activator, induces a significant antitumor activity *in vitro* and tumor growth delay in a mouse xenograft model of colorectal cancer (68). The mechanism through which Compound 1 activates AMPK, is however, still uncharacterized.

Taken together, the induction of a persistent, supra-physiological activation of AMPK results in tumor suppression in some cancer types (Fig. 3).

Salicylate, the active metabolite of aspirin following absorption from the gut, was recently identified as a direct AMPK activator, which binds to the same site on the $\beta 1$ subunit as A-769662 (69). This suggests that AMPK activation might be involved in mediating aspirin's protective effects against cancer. Future pre-clinical studies in genetically engineered AMPK models are however required to validate this hypothesis.

Overall, these apparently conflicting data suggest that both AMPK activators and inhibitors can provide therapeutic benefit in different tumor types, different genetic/metabolic contexts, and different microenvironment conditions. Thus, the choice of AMPK modulators may be different at various phases of tumorigenesis/tumor progression.

AMPK role in cancer: Human studies

AMPK activation in human cancers

Evaluation of AMPK activation in human tissues is not trivial. Early studies have demonstrated that when tissues and organs are removed by dissection at ambient temperature rather than by freeze clamping, ACC phosphorylation both occurred as a post-mortem artifact. Dissection at ambient temperature leads to elevation of AMP and depletion of ATP, presumably due to hypoxia following interruption of the blood supply, resulting in AMPK activation. Moreover, ACC phosphorylation in tissues such as liver has also been shown to follow a diurnal rhythm and to be influenced by dietary behavior (70). Therefore, analysis of AMPK activity and ACC phosphorylation in human tissues should be interpreted with caution.

AMPK activation has been investigated in fresh frozen and archival tumor tissue from numerous cancer sites, including prostate (63, 71, 72), breast (73, 74), head and neck (75), colorectal (76, 77), gastric (78, 79), liver (80), lung (81–83), ovary (84), and kidney (85, 86). Table 1 summarizes the population-based studies of AMPK activation, measured by protein expression of phosphorylated AMPK α 1 (p-AMPK α 1, n=16 studies) or its phosphorylated substrate ACC (p-ACC, n=6 studies), with cancer prognosis and clinicopathologic features. Of the 13 studies reporting on p-AMPK α 1 at Thr172 and overall, cancer-specific, or progression-free survival, 8 studies found that AMPK activation was associated with improved prognosis among head and neck (75), colorectal (76, 77), gastric (79), liver (80), lung (81), and kidney (85, 86) cancer patients either within the entire study population or within subgroups. Consistent with the findings for p-AMPK α 1 at Thr172, one additional study of lung cancer found that higher expression of p-AMPK α 1 at Ser485, which inhibits AMPK signaling (14), was associated with shorter survival (82). Conversely, two studies in gastric cancer (78) and in prostate cancer (72) reported associations between higher p-AMPK α 1 and disease recurrence; however, the gastric cancer study population was substantially smaller than that of Kim et al. (79). Three additional studies in lung (83) and breast cancer patients (73, 74) found no association between p-AMPK α 1 expression and overall survival. In cross-sectional analyses, higher p-AMPK α 1 expression was associated with lower tumor grade and/or stage in breast (73), head and neck (75), colorectal (76), gastric (79), liver (80), and ovarian (84) cancer, while 4 additional studies in prostate (72), breast (74), gastric (78), and lung (81) cancer found no associations with clinicopathologic features. In contrast, Choudhury et al. found increasing p-AMPK α 1 expression with higher tumor grade in prostate cancer specimens (63). Overall, these human studies support the hypothesis that AMPK activation may delay disease progression in several cancer types.

Of the 6 studies that used protein expression of p-ACC at Ser79 to characterize AMPK activation, higher p-ACC was associated with worse overall survival (82) and disease recurrence (83) among lung cancer patients, and with worse overall survival among head

and neck cancer (75) and kidney cancer (86) patients. In contrast, higher p-ACC was associated with improved overall survival and progression-free survival in colorectal cancer patients (77). Lastly, no correlation was observed between p-ACC expression and Gleason grade in prostate tumors (71). A better understanding of the effects of ACC inactivation and its downstream targets in different tumor tissues will help elucidate the complex role of AMPK activation in carcinogenesis.

Tumor expression of specific AMPK α , β , and γ subunits in relation to cancer outcomes has been explored in patients with melanoma (87), kidney cancer (85, 86), breast cancer (74), cervical cancer (88), lymphoma (89), ovarian cancer (84, 90, 91), lung cancer (82), and colorectal cancer (92). Total AMPK α 1 protein expression, which captures both phosphorylated and non-phosphorylated AMPK α 1, was associated with improved overall and disease-specific survival among 128 melanoma patients (87). Total AMPK α 1/ α 2 protein expression was associated with improved progression-free survival ($p=0.04$) and borderline associated with overall survival ($p=0.06$) in 37 renal cell carcinoma patients (85). Using publicly available data from the Cancer Genome Atlas (TCGA), overexpression of the genes encoding for AMPK α 1, α 2, β 1, β 2, and γ 1 subunits were also associated with improved overall survival ($p \leq 0.05$) in 417 clear cell renal cell carcinoma patients (86). In a discovery ($n=166$) and validation ($n=609$) cohort of breast cancer patients, total AMPK α expression was associated with longer relapse-free ($p=0.016$ and $p=0.06$, respectively) and breast cancer-specific ($p<0.001$ and $p=0.005$, respectively) survival (74). Using fluorescence *in situ* hybridization, amplification of the gene encoding AMPK α 1 was not significantly associated with lymph node positivity ($p=0.085$) in pretreatment cervical biopsies among 31 cervical cancer patients (88). Using the Oncomine database, Hoffman et al. reported an association between higher expression of the genes encoding the regulatory AMPK β 1 and β 2 subunits and increased 5-year survival ($p=0.001$ and 0.021 , respectively) among diffuse large B cell lymphoma patients; marginal associations were found for higher expression of the gene encoding AMPK α 1 and improved survival ($p=0.0751$), and higher expression of the gene encoding AMPK γ 3 and worse survival ($p=0.0646$) (89). Similarly in a series of 70 ovarian cancer patients, higher protein expression of p-AMPK γ 1 at Ser182 was associated with lower tumor grade ($n=70$, $p=0.009$) and improved overall survival in the subgroup of patients with serous subtype ($n=46$, $p=0.037$) and advanced-stage disease ($n=54$, $p=0.0016$) (90). Phosphorylation of AMPK γ 1 at Ser182 has not been shown to affect the kinase activity, but is associated with nuclear localization (93). Another study of total AMPK γ 1 in ovarian cancer also found that higher protein expression was associated with early tumor stage ($p=0.008$), lower tumor grade ($p=0.013$), and absence of metastasis ($p=0.008$) (84). This same research group previously demonstrated that higher expression of the gene encoding AMPK α 2, measured by quantitative PCR, was associated with improved overall ($p=0.030$) and disease-free ($p=0.014$) survival in a hospital-based series of 76 ovarian cancer patients, though gene expression of the α 1, β 1, β 2, γ 1, and γ 2 subunits were not associated with outcomes (91). Zupa et al., in addition to the findings for p-AMPK α 1 and p-ACC listed in Table 1, reported an association between higher protein expression of p-AMPK β 1 at Ser108, indicative of AMPK activation (93), and short- vs. long-term survival ($p=0.0286$) among 28 pathologic stage N0 non-small-cell lung cancer patients (82). Lastly, Vetvik et al. found that tumor expression of the gene encoding AMPK β 1 was positively correlated with

advanced tumor stage, but not with the number of affected lymph nodes, in specimens from 60 colorectal cancer patients (92).

With the exception of Zupa et al. and Vetvik et al., these studies suggest that higher tumor expression of specific AMPK subunits may be related to favorable clinicopathologic features and improved outcomes among cancer patients. Additional studies are warranted to confirm these findings in larger study populations and across cancer sites.

Differential expression of AMPK/ACC in tumor vs. normal tissue has been reported in a few neoplasms, including liver (80), ovarian (90, 91), thyroid (94), cervical (95), brain (47), skin (87), prostate (63, 71, 72, 96), and colorectal cancer (92). In hepatocellular carcinoma, protein expression of p-AMPK α 1 at Thr172 was downregulated in 62% of tumor vs. distant normal liver tissue (80). In ovarian specimens, protein expression of p-AMPK β 1 at Ser182 was significantly higher ($p=0.038$) in carcinoma compared to borderline tumors and normal ovaries (90). Li et al. also found higher expression of the genes encoding AMPK α 2, β 1, β 2, γ 1, and γ 2 ($p < 0.001$), but not AMPK α 1 ($p=0.320$), in primary cancer vs. normal ovarian tissue (91). In papillary thyroid carcinoma patients, protein expression of total AMPK α , p-AMPK α 1 at Thr172, and p-ACC at Ser79 was elevated ($p<0.001$) in carcinoma vs. paired non-neoplastic tissue (94). Similarly, protein expression of AMPK α 1 was significantly higher ($p<0.001$) in tumor vs. normal epithelium in cervical cancer patients (95). In a small study of brain cancer, high protein expression of p-ACC at Ser79 was seen in all glioblastoma specimens compared to absence of expression in normal brain (47). In melanoma patients, total AMPK α 1 protein expression was increased in primary melanoma vs. dysplastic nevi ($p<0.005$), but slightly decreased in metastatic vs. primary melanoma specimens ($p<0.05$) (87). In prostate cancer patients, both p-AMPK α 1 at Thr172 and p-ACC at Ser79 were expressed in tumor tissue, compared to no detectable expression in non-paired benign prostate hyperplasia samples (63). Two additional prostate studies reported elevated expression of p-AMPK α 1 at Thr172 and p-ACC at Ser79 ($p<0.001$) in prostate tumor vs. non-neoplastic tissue (71, 72). Utilizing the Oncomine database, the gene encoding AMPK β 1 was expressed at greater levels in metastatic vs. primary prostate cancer in publicly available data from 4 studies (96). Lastly, expression of the gene encoding AMPK β 1 was significantly higher in colorectal cancer vs. adjacent mucosa (92). Taken together, these studies support that AMPK dysregulation contributes to neoplastic transformation.

In summary, AMPK expression/activation varies by tumor stage and histology, clinical outcomes, and tissue type (normal, tumor, metastatic). Most of the studies in tumor tissue support a role of AMPK activation, measured by phosphorylation at Thr172, in delaying tumor progression. However, comparing tumor to non-neoplastic tissue suggests that AMPK may be involved in tumor initiation. Thus, evidence from human studies also underscores the dual role of AMPK in carcinogenesis.

AMPK-activating drugs in humans: metformin, phenformin, and aspirin

Several review articles and meta-analyses on metformin and cancer risk have been published in recent years. A 2012 meta-analysis of randomized controlled trials among participants with or at risk of type 2 diabetes did not find reduced cancer incidence for treatment with

metformin vs. placebo/usual care or active comparators (n=9 studies; summary relative risk (RR): 1.02; 95% confidence interval (CI): 0.82–1.26) (97). Meta-analyses of observational studies among diabetics have shown a reduced risk of cancer associated with metformin use: the fixed-effect summary RRs [95% CI] were 0.70 [0.67–0.73] for 9 cohort studies (98), 0.90 [0.84–0.98] for 13 case-control studies (98), and 0.73 [0.61–0.88] for 21 cohort and case-control studies combined (99). However, both meta-analyses exhibited significant between-study heterogeneity, with Thakkar et al. reporting random-effects model estimates that were attenuated (summary RR: 0.85; 95% CI: 0.65–1.11) among cohort studies, but retained significance (summary RR: 0.71; 95% CI: 0.57–0.88) among case-control studies (98). Inconsistent results may be due to variations in metformin dose, duration of metformin use, length of follow-up, type of comparison group (diabetics taking non-metformin anti-diabetic medications, diabetics on alternative therapy, or non-diabetics), outcome assessed (incident cancer or cancer mortality as a surrogate), variation by cancer site, systematic biases, or confounding. Of particular concern are potential time-related biases that may arise when evaluating metformin and cancer risk (100). A recent meta-analysis of observational and randomized studies attempted to account for major biases and confounders, still finding a significant, though attenuated, reduction in cancer incidence among studies without time-related biases (n=8 studies; summary RR: 0.90; 95% CI: 0.89–0.91) and among studies adjusted for body mass index (n=11 studies; summary RR: 0.82; 95% CI: 0.70–0.96) (101). Observational studies published after these meta-analyses have either been consistent with reduced cancer risk (102, 103) or null (104–106). Overall, the literature suggests that metformin either reduces or has no effect on cancer risk, though very few studies have addressed metformin use in the non-diabetic population. Future clinical trials of metformin therapy in the general population should provide vital data on the potential use of metformin as a chemopreventive agent.

Metformin use may also influence disease progression after a cancer diagnosis. In observational studies, metformin has been associated with a decreased risk of disease recurrence, overall mortality, or cancer-specific mortality in patient cohorts of prostate cancer (107, 108), multiple myeloma (109), liver cancer (110), ovarian/endometrial cancer (110–112), bladder cancer (113, 114) and breast cancer (115, 116). Two additional studies of prostate cancer patients who underwent radical prostatectomy found no significant associations between metformin use and time to biochemical recurrence or longer-term outcomes (117, 118). Two additional studies of breast cancer patients were null for metformin use and overall or cancer-specific survival (119, 120). Numerous clinical trials of metformin as an adjuvant therapy to cancer treatment are underway as indicated on ClinicalTrials.gov. Combined with the observational data, these new clinical trials will shed light on the potential therapeutic role of metformin in cancer survivors.

In addition, a limited number of ‘window of opportunity’ (i.e. phase 0) trials have been conducted to evaluate metformin administration in the time window between cancer diagnosis and surgery. These studies show mixed results for tumor p-AMPK α at Thr172 expression before and after metformin use (ranging from 850–2250 mg/day): p-AMPK α protein expression was increased in one study of endometrial cancer patients (121), decreased in another study of endometrial cancer patients (122), and unchanged in two

studies of endometrial (123) and prostate (124) cancer patients. Thus, a direct link between short-term metformin use and AMPK activation in targeted tissue is unclear. Larger studies of longer duration and varying dosage of metformin use across various cancer types are needed to determine whether metformin acts through the AMPK pathway to influence tumor growth and progression.

Phenformin, a metformin analog, is also a potent indirect activator of AMPK and was administered as anti-diabetic medication starting in the mid-1900s. However, increased risk of lactic acidosis, often fatal, led to the withdrawal of phenformin by the US Food and Drug Administration in 1977 (125). Phenformin has a longer half-life and displays more potent anti-neoplastic activity compared to metformin in *in vitro* and *in vivo* pre-clinical studies (126). *In vitro* studies of the antitumorigenic effects of metformin are often at supra-physiological concentrations that may be unattainable in humans, thus phenformin may offer an alternative for chemoprevention or adjuvant therapy for cancer patients. Phenformin continues to be available in some parts of the world. In a recent cohort study of biguanide use and colorectal cancer risk in Denmark, phenformin comprised 0.5% of biguanide prescriptions (127). The investigators analyzed all biguanides as a group and found an increased risk of colorectal cancer among biguanide users compared to non-diabetics, and risk estimates were inconsistent when biguanide users were compared to diabetics on other oral anti-diabetic drugs. These results conflict with much of the current literature suggesting a reduced risk or null association for biguanide treatment and colorectal cancer incidence (99).

More recently, salicylate, the metabolic derivative of aspirin, has been shown to directly activate AMPK (69). Aspirin has long been known to exhibit antineoplastic properties, though whether these properties are mediated by AMPK is unknown. Algra et al. summarized the results for any aspirin use and long-term cancer incidence, reporting summary RRs [95% CI] of 0.88 [0.84–0.92] among 150 case-control studies and 0.87 [0.83–0.91] among 45 cohort studies for risk of all cancer types, with the most consistent findings for reduced risk of colorectal cancer (128). Rothwell et al. summarized the results for regular aspirin use and cancer incidence and mortality among randomized controlled trials for the primary prevention of cardiovascular disease, reporting summary RRs [95% CI] of 0.88 [0.80–0.98] for cancer risk among 6 trials and 0.85 [0.76–0.96] for cancer deaths among 34 trials (129). This group also found that aspirin use among patients with non-metastatic adenocarcinoma at diagnosis was associated with a reduced risk of subsequent metastasis (summary RR=0.45; 95% CI: 0.28–0.72) and cancer death (summary RR=0.50; 95% CI: 0.34–0.74) among 5 randomized trials of daily aspirin for the prevention of vascular events (130). Additional observational studies support an association between regular aspirin use after diagnosis and improved survival outcomes among breast (131, 132), colorectal [(133–137), reviewed in (138)], and prostate cancer (139, 140) patients, while other studies do not (141–144). Overall, the current evidence from long-term observational and randomized studies is strongly suggestive of a potential role for aspirin in the primary and secondary prevention of cancer.

In summary, observational and randomized studies suggest a potential benefit of AMPK-activating drugs for chemoprevention and/or improving cancer survival. These findings are

in agreement with associations between AMPK activation levels in tumor tissue and more favorable clinicopathologic features and survival outcomes observed in several cancer types (Table 1). In future studies, it will be important to understand to what extent AMPK activation mediates the ability of these drugs to reduce cancer risk, and to define their action in the context of the metabolic status of the individual, concurrent medication use, and the natural history of cancer.

Conclusions

The duplicitous role of AMPK activation in cancer cells is context-specific and affects the outcome of AMPK modulation. More sophisticated genetic manipulation of AMPK is necessary to understand its biochemical and cell biology function in the different contexts. In addition, knowledge of long-term outcomes in healthy individuals and cancer patients in relation to AMPK status is necessary to inform the potential use of AMPK modulators in the clinical setting. Thus, the road towards a deeper understanding of AMPK's role in cancer and its therapeutic exploitation is still under construction.

Acknowledgments

Financial Support: This work was supported by NIH/NCI grant 2R01CA131945, the DF/HCC SPORE in Prostate Cancer (NIH/NCI P50 CA90381), the Prostate Cancer Foundation, the DOD synergist idea development award (PC130716) to M.L. J.L.B. is supported, in part, by the Department of Defense Prostate Cancer Research Program (W81XWH-12-1-0072) and the Dana-Farber Cancer Institute Mazzone Awards Program.

References

1. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *Journal of Biology*. 2003; 2:28. [PubMed: 14511394]
2. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Current Biology*. 2003; 13:2004–8. [PubMed: 14614828]
3. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc Natl Acad Sci U S A*. 2004; 101:3329–35. [PubMed: 14985505]
4. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. *Biochim Biophys Acta*. 2010; 1804:581–91. [PubMed: 19778642]
5. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. *Nat Cell Biol*. 2011; 13:1016–23. [PubMed: 21892142]
6. Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor? *Cancer Res*. 2013; 73:2929–35. [PubMed: 23644529]
7. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013; 6:pl1. [PubMed: 23550210]
8. Li J, Jiang P, Robinson M, Lawrence TS, Sun Y. AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. *Carcinogenesis*. 2003; 24:827–34. [PubMed: 12771025]
9. Fox MM, Phoenix KN, Kopsiaftis SG, Claffey KP. AMP-Activated Protein Kinase alpha 2 Isoform Suppression in Primary Breast Cancer Alters AMPK Growth Control and Apoptotic Signaling. *Genes Cancer*. 2013; 4:3–14. [PubMed: 23946867]

10. Lee CW, Wong LL, Tse EY, Liu HF, Leong VY, Lee JM, et al. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. *Cancer Res.* 2012; 72:4394–404. [PubMed: 22728651]
11. Xiao B, Heath R, Saiu P, Leiper FC, Leone P, Jing C, et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. *Nature.* 2007; 449:496–500. [PubMed: 17851531]
12. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, et al. Structure of mammalian AMPK and its regulation by ADP. *Nature.* 2011; 472:230–3. [PubMed: 21399626]
13. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. *Nat Rev Mol Cell Biol.* 2012; 13:251–62. [PubMed: 22436748]
14. Steinberg GR, Kemp BE. AMPK in Health and Disease. *Physiol Rev.* 2009; 89:1025–78. [PubMed: 19584320]
15. Goransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. *J Biol Chem.* 2007; 282:32549–60. [PubMed: 17855357]
16. Emerling BM, Weinberg F, Snyder C, Burgess Z, Mutlu GM, Viollet B, et al. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. *Free Radic Biol Med.* 2009; 46:1386–91. [PubMed: 19268526]
17. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. *Future Oncol.* 2010; 6:457–70. [PubMed: 20222801]
18. DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, et al. Energy Stress Regulates Hippo-YAP Signaling Involving AMPK-Mediated Regulation of Angiotensin-like 1 Protein. *Cell Rep.* 2014; 9:495–503. [PubMed: 25373897]
19. Jeon SM, Hay N. The dark face of AMPK as an essential tumor promoter. *Cell Logist.* 2012; 2:197–202. [PubMed: 23676995]
20. Bon H, Wadhwa K, Schreiner A, Osborne M, Carroll T, Ramos-Montoya A, et al. Salt-Inducible Kinase 2 Regulates Mitotic Progression and Transcription in Prostate Cancer. *Molecular Cancer Research.* 2014
21. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. *Cell Metab.* 2013; 17:113–24. [PubMed: 23274086]
22. Scaglia N, Tyekucheva S, Zadra G, Photopoulos C, Loda M. De novo fatty acid synthesis at the mitotic exit is required to complete cellular division. *Cell Cycle.* 2014; 13:859–68. [PubMed: 24418822]
23. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylase- α gene induces growth inhibition and apoptosis of prostate cancer cells. *Cancer Res.* 2005; 65:6719–25. [PubMed: 16061653]
24. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase α is essential to breast cancer cell survival. *Cancer Res.* 2006; 66:5287–94. [PubMed: 16707454]
25. Lee JH, Koh H, Kim M, Kim Y, Lee SY, Karess RE, et al. Energy-dependent regulation of cell structure by AMP-activated protein kinase. *Nature.* 2007; 447:1017–20. [PubMed: 17486097]
26. Banko MR, Allen JJ, Schaffer BE, Wilker EW, Tsou P, White JL, et al. Chemical genetic screen for AMPK α 2 substrates uncovers a network of proteins involved in mitosis. *Mol Cell.* 2011; 44:878–92. [PubMed: 22137581]
27. Thaiparambil JT, Eggers CM, Marcus AI. AMPK regulates mitotic spindle orientation through phosphorylation of myosin regulatory light chain. *Molecular and Cellular Biology.* 2012; 32:3203–17. [PubMed: 22688514]
28. Vazquez-Martin A, Oliveras-Ferraro C, Menendez JA. The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. *Cell Cycle.* 2009; 8:2385–98. [PubMed: 19556893]
29. Vazquez-Martin A, Oliveras-Ferraro C, Lopez-Bonet E, Menendez JA. AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. *Cell Cycle.* 2009; 8:3679–83. [PubMed: 19844168]

30. Merlen G, Gentric G, Celton-Morizur S, Foretz M, Guidotti JE, Fauveau V, et al. AMPK α 1 controls hepatocyte proliferation independently of energy balance by regulating Cyclin A2 expression. *Journal of Hepatology*. 2014; 60:152–9. [PubMed: 24012615]
31. Shen CH, Yuan P, Perez-Lorenzo R, Zhang Y, Lee SX, Ou Y, et al. Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. *Mol Cell*. 2013; 52:161–72. [PubMed: 24095280]
32. Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, et al. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. *Cancer Res*. 2014; 74:4783–95. [PubMed: 24994714]
33. Pineda CT, Ramanathan S, Fon Tacer K, Weon JL, Potts MB, Ou YH, et al. Degradation of AMPK by a cancer-specific ubiquitin ligase. *Cell*. 2015; 160:715–28. [PubMed: 25679763]
34. Horman S, Vertommen D, Heath R, Neumann D, Mouton V, Woods A, et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase α -subunits in heart via hierarchical phosphorylation of Ser485/491. *J Biol Chem*. 2006; 281:5335–40. [PubMed: 16340011]
35. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, et al. Oncogenic B-Raf negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. *Mol Cell*. 2009; 33:237–47. [PubMed: 19187764]
36. Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. *J Clin Invest*. 2013; 123:2907–20. [PubMed: 23921130]
37. Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. *Cancer Cell*. 2011; 20:315–27. [PubMed: 21907923]
38. Rodriguez M, Potter DA. CYP1A1 regulates breast cancer proliferation and survival. *Molecular Cancer Research*. 2013; 11:780–92. [PubMed: 23576571]
39. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science*. 2011; 331:456–61. [PubMed: 21205641]
40. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. *Biochem Soc Trans*. 2002; 30:1064–70. [PubMed: 12440973]
41. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. *Genes Dev*. 2011; 25:1041–51. [PubMed: 21576264]
42. Bungard D, Fuerth BJ, Zeng PY, Faubert B, Maas NL, Viollet B, et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. *Science*. 2010; 329:1201–5. [PubMed: 20647423]
43. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. *Nature*. 2012; 485:661–5. [PubMed: 22660331]
44. Zhong D, Liu X, Khuri FR, Sun SY, Vertino PM, Zhou W. LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. *Cancer Res*. 2008; 68:7270–7. [PubMed: 18794113]
45. Vincent EE, Coelho PP, Blagih J, Griss T, Viollet B, Jones RG. Differential effects of AMPK agonists on cell growth and metabolism. *Oncogene*. 2014
46. Laderoute KR, Calaoagan JM, Chao WR, Dinh D, Denko N, Duellman S, et al. 5'-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors. *J Biol Chem*. 2014; 289:22850–64. [PubMed: 24993821]
47. Rios M, Foretz M, Viollet B, Prieto A, Fraga M, Costoya JA, et al. AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. *Cancer Res*. 2013; 73:2628–38. [PubMed: 23370326]
48. Rios M, Foretz M, Viollet B, Prieto A, Fraga M, Garcia-Caballero T, et al. Lipoprotein internalisation induced by oncogenic AMPK activation is essential to maintain glioblastoma cell growth. *Eur J Cancer*. 2014; 50:3187–97. [PubMed: 25450947]

49. Hindupur SK, Balaji SA, Saxena M, Pandey S, Sravan GS, Heda N, et al. Identification of a novel AMPK-PEA15 axis in the anoikis-resistant growth of mammary cells. *Breast Cancer Research*. 2014; 16:420. [PubMed: 25096718]
50. Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR, et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. *Nature*. 2012; 483:608–12. [PubMed: 22460906]
51. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. *Biochem J*. 2000; 348(Pt 3):607–14. [PubMed: 10839993]
52. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *BMJ*. 2005; 330:1304–5. [PubMed: 15849206]
53. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. *Cell Metab*. 2010; 11:390–401. [PubMed: 20444419]
54. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. *Cancer Res*. 2011; 71:4366–72. [PubMed: 21540236]
55. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. *Clin Sci (Lond)*. 2012; 122:253–70. [PubMed: 22117616]
56. Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, Chow LM, et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. *Proc Natl Acad Sci U S A*. 2014; 111:E435–44. [PubMed: 24474794]
57. Hardie DG, Alessi DR. LKB1 and AMPK and the cancer-metabolism link - ten years after. *BMC Biol*. 2013; 11:36. [PubMed: 23587167]
58. Faubert B, Vincent EE, Poffenberger MC, Jones RG. The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. *Cancer Lett*. 2015; 356:165–70. [PubMed: 24486219]
59. Laderoute KR, Calaoagan JM, Madrid PB, Klon AE, Ehrlich PJ. SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK). *Cancer Biology & Therapy*. 2010; 10:68–76. [PubMed: 20495370]
60. Huang X, Wulschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. *Biochem J*. 2008; 412:211–21. [PubMed: 18387000]
61. Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. *Clin Transl Oncol*. 2014; 16:746–52. [PubMed: 24338509]
62. Lea MA, Pourat J, Patel R, desBordes C. Growth inhibition of colon cancer cells by compounds affecting AMPK activity. *World Journal of Gastrointestinal Oncology*. 2014; 6:244–52. [PubMed: 25024815]
63. Choudhury Y, Yang Z, Ahmad I, Nixon C, Salt IP, Leung HY. AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. *Oncoscience*. 2014; 1:446–56. [PubMed: 25594043]
64. Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, et al. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. *J Biol Chem*. 2011; 286:39247–58. [PubMed: 21917926]
65. Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. *EMBO Mol Med*. 2014; 6:519–38. [PubMed: 24497570]
66. Jurmeister S, Ramos-Montoya A, Neal DE, Fryer LG. Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. *Oncotarget*. 2014; 5:3785–99. [PubMed: 25003216]
67. Shen M, Zhang Z, Ratnam M, Dou QP. The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells. *J Cell Physiol*. 2014; 229:688–95. [PubMed: 24129850]

68. Valtorta S, Nicolini G, Tripodi F, Meregalli C, Cavaletti G, Avezza F, et al. A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. *Invest New Drugs*. 2014; 32:1123–33. [PubMed: 25134489]
69. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. *Science*. 2012; 336:918–22. [PubMed: 22517326]
70. Davies SP, Carling D, Munday MR, Hardie DG. Diurnal rhythm of phosphorylation of rat liver acetyl-CoA carboxylase by the AMP-activated protein kinase, demonstrated using freeze-clamping. Effects of high fat diets. *European Journal of Biochemistry*. 1992; 203:615–23. [PubMed: 1346520]
71. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. *Mol Cancer Ther*. 2009; 8:733–41. [PubMed: 19372545]
72. Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1 α -mediated metabolic switch. *Oncogene*. 2014; 33:5251–61. [PubMed: 24186207]
73. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, et al. Histological evaluation of AMPK signalling in primary breast cancer. *BMC Cancer*. 2009; 9:307. [PubMed: 19723334]
74. Zhang Y, Storr SJ, Johnson K, Green AR, Rakha EA, Ellis IO, et al. Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. *Oncotarget*. 2014; 5:12936–49. [PubMed: 25427448]
75. Su YW, Lin YH, Pai MH, Lo AC, Lee YC, Fang IC, et al. Association between phosphorylated AMP-activated protein kinase and acetyl-CoA carboxylase expression and outcome in patients with squamous cell carcinoma of the head and neck. *PLoS One*. 2014; 9:e96183. [PubMed: 24769813]
76. Baba Y, Noshio K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, et al. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. *Br J Cancer*. 2010; 103:1025–33. [PubMed: 20808308]
77. Zulato E, Bergamo F, De Paoli A, Griguolo G, Esposito G, De Salvo GL, et al. Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. *Br J Cancer*. 2014; 111:25–32. [PubMed: 24892446]
78. Kang BW, Jeong JY, Chae YS, Lee SJ, Lee YJ, Choi JY, et al. Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy. *Cancer Chemother Pharmacol*. 2012; 70:735–41. [PubMed: 22955258]
79. Kim JG, Lee SJ, Chae YS, Kang BW, Lee YJ, Oh SY, et al. Association between phosphorylated AMP-activated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer. *Oncology*. 2013; 85:78–85. [PubMed: 23860205]
80. Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. *Clin Cancer Res*. 2013; 19:5372–80. [PubMed: 23942093]
81. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, et al. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. *Ann Oncol*. 2012; 23:78–85. [PubMed: 21430184]
82. Zupa A, Imprata G, Silvestri A, Pin E, Deng J, Aieta M, et al. A pilot characterization of human lung NSCLC by protein pathway activation mapping. *J Thorac Oncol*. 2012; 7:1755–66. [PubMed: 23154546]
83. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, et al. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. *J Thorac Oncol*. 2010; 5:1894–904. [PubMed: 21124077]

84. Li C, Liu VW, Chiu PM, Yao KM, Ngan HY, Chan DW. Reduced expression of AMPK-beta1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. *Mol Cancer*. 2014; 13:49. [PubMed: 24602453]
85. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. *Ann Oncol*. 2010; 21:1599–606. [PubMed: 20089566]
86. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*. 2013; 499:43–9. [PubMed: 23792563]
87. Bhandaru M, Martinka M, Li G, Rotte A. Loss of AMPKalpha1 expression is associated with poor survival in melanoma patients. *J Invest Dermatol*. 2014; 134:1763–6. [PubMed: 24441100]
88. Wangsa D, Heselmeyer-Haddad K, Ried P, Eriksson E, Schaffer AA, Morrison LE, et al. Fluorescence in situ hybridization markers for prediction of cervical lymph node metastases. *Am J Pathol*. 2009; 175:2637–45. [PubMed: 19893027]
89. Hoffman AE, Demanelis K, Fu A, Zheng T, Zhu Y. Association of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma. *Cancer Epidemiol Biomarkers Prev*. 2013; 22:736–44. [PubMed: 23396962]
90. Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, et al. Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. *Oncol Rep*. 2011; 25:1005–12. [PubMed: 21271224]
91. Li C, Liu VW, Chiu PM, Chan DW, Ngan HY. Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications. *BMC Cancer*. 2012; 12:357. [PubMed: 22897928]
92. Vetvik KK, Sonerud T, Lindeberg M, Luders T, Storkson RH, Jonsdottir K, et al. Globular adiponectin and its downstream target genes are up-regulated locally in human colorectal tumors: ex vivo and in vitro studies. *Metabolism*. 2014; 63:672–81. [PubMed: 24636346]
93. Warden SM, Richardson C, O'Donnell J Jr, Stapleton D, Kemp BE, Witters LA. Post-translational modifications of the beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. *Biochem J*. 2001; 354:275–83. [PubMed: 11171104]
94. Vidal AP, Andrade BM, Vaisman F, Cazarin J, Pinto LF, Breitenbach MM, et al. AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer. *Eur J Endocrinol*. 2013; 169:521–8. [PubMed: 23904275]
95. Huang FY, Chiu PM, Tam KF, Kwok YK, Lau ET, Tang MH, et al. Semi-quantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer. *Gynecol Oncol*. 2006; 103:219–25. [PubMed: 16595147]
96. Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, et al. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. *Cancer Discovery*. 2012; 2:328–43. [PubMed: 22576210]
97. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. *Diabetologia*. 2012; 55:2593–603. [PubMed: 22875195]
98. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. *Metabolism*. 2013; 62:922–34. [PubMed: 23419783]
99. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. *PLoS One*. 2013; 8:e71583. [PubMed: 23936520]
100. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. *Diabetes Care*. 2012; 35:2665–73. [PubMed: 23173135]
101. Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. *Cancer Prev Res (Phila)*. 2014; 7:867–85. [PubMed: 24985407]

102. Kim YI, Kim SY, Cho SJ, Park JH, Choi IJ, Lee YJ, et al. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. *Aliment Pharmacol Ther.* 2014; 39:854–63. [PubMed: 24612291]
103. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, et al. Metformin use and prostate cancer risk. *Eur Urol.* 2014; 66:1012–20. [PubMed: 24857538]
104. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. *Diabetes Care.* 2014; 37:2522–32. [PubMed: 24898303]
105. Luo J, Beresford S, Chen C, Chlebowski R, Garcia L, Kuller L, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. *Br J Cancer.* 2014; 111:1432–9. [PubMed: 25051408]
106. Mamtani R, Pfanzer N, Haynes K, Finkelman BS, Wang X, Keefe SM, et al. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. *Diabetes Care.* 2014; 37:1910–7. [PubMed: 24496803]
107. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. *J Clin Oncol.* 2013; 31:3069–75. [PubMed: 23918942]
108. He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. *Ann Oncol.* 2011; 22:2640–5. [PubMed: 21415239]
109. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. *Br J Cancer.* 2014; 111:628–36. [PubMed: 24921909]
110. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. *Diabetes Care.* 2012; 35:299–304. [PubMed: 22266734]
111. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al. Metformin is associated with improved survival in endometrial cancer. *Gynecol Oncol.* 2014; 132:438–42. [PubMed: 24269517]
112. Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, et al. Metformin use and endometrial cancer survival. *Gynecol Oncol.* 2014; 132:236–40. [PubMed: 24189334]
113. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. *BJU Int.* 2013; 112:1105–12. [PubMed: 24053906]
114. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. *Urol Oncol.* 2014; 32:49.e7–14. [PubMed: 24140245]
115. Peeters PJ, Bazelier MT, Vestergaard P, Leufkens HG, Schmidt MK, de Vries F, et al. Use of metformin and survival of diabetic women with breast cancer. *Curr Drug Saf.* 2013; 8:357–63. [PubMed: 24215316]
116. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. *Ann Oncol.* 2012; 23:1771–80. [PubMed: 22112968]
117. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. *Prostate Cancer Prostatic Dis.* 2013; 16:391–7. [PubMed: 24100644]
118. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ. Effect of metformin on prostate cancer outcomes after radical prostatectomy. *Urol Oncol.* 2014; 32:43.e1–7. [PubMed: 23810664]
119. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: a population-based study. *Diabetes Care.* 2013; 36:3018–26. [PubMed: 23633525]

120. Bayraktar S, Hernandez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. *Cancer*. 2012; 118:1202–11. [PubMed: 21800293]
121. Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. *Cancer*. 2014; 120:2986–95. [PubMed: 24917306]
122. Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L, et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. *Cancer Med*. 2015; 4:161–73. [PubMed: 25417601]
123. Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, et al. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. *Gynecol Oncol*. 2014; 134:607–14. [PubMed: 24972190]
124. Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, et al. A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer. *Prostate Cancer Prostatic Dis*. 2014; 17:252–8. [PubMed: 24861559]
125. Kwong SC, Brubacher J. Phenformin and lactic acidosis: a case report and review. *J Emerg Med*. 1998; 16:881–6. [PubMed: 9848705]
126. Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. *Nature Reviews: Endocrinology*. 2014; 10:143–56.
127. Knapen LM, Dittich ST, de Vries F, Starup-Linde J, Vestergaard P, Henry RM, et al. Use of biguanides and the risk of colorectal cancer: a register-based cohort study. *Curr Drug Saf*. 2013; 8:349–56. [PubMed: 24215310]
128. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. *Lancet Oncol*. 2012; 13:518–27. [PubMed: 22440112]
129. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *Lancet*. 2012; 379:1602–12. [PubMed: 22440946]
130. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *Lancet*. 2012; 379:1591–601. [PubMed: 22440947]
131. Fraser DM, Sullivan FM, Thompson AM, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. *Br J Cancer*. 2014; 111:623–7. [PubMed: 24945997]
132. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. *J Clin Oncol*. 2010; 28:1467–72. [PubMed: 20159825]
133. McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. *Eur J Cancer*. 2013; 49:1049–57. [PubMed: 23182687]
134. Reimers MS, Bastiaannet E, van Herk-Sukel MP, Lemmens VE, van den Broek CB, van de Velde CJ, et al. Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. *J Am Geriatr Soc*. 2012; 60:2232–6. [PubMed: 23176157]
135. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. *N Engl J Med*. 2012; 367:1596–606. [PubMed: 23094721]
136. Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. *Br J Cancer*. 2012; 107:1602–7. [PubMed: 23011483]
137. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. *Br J Cancer*. 2012; 106:1564–70. [PubMed: 22454078]
138. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. *Nat Rev Clin Oncol*. 2012; 9:561–70. [PubMed: 22910681]

139. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. *J Clin Oncol*. 2012; 30:3540–4. [PubMed: 22927523]
140. Flahavan EM, Bennett K, Sharp L, Barron TI. A cohort study investigating aspirin use and survival in men with prostate cancer. *Ann Oncol*. 2014; 25:154–9. [PubMed: 24356627]
141. Cardwell CR, Flahavan EM, Hughes CM, Coleman HG, O'Sullivan JM, Powe DG, et al. Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. *Cancer Causes Control*. 2014; 25:33–43. [PubMed: 24310109]
142. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. *Cancer Prev Res (Phila)*. 2012; 5:1223–8. [PubMed: 22961777]
143. Holmes MD, Olsson H, Pawitan Y, Holm J, Lundholm C, Andersson TM, et al. Aspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in Sweden. *BMC Cancer*. 2014; 14:391. [PubMed: 24890520]
144. Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, et al. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. *Gastroenterology*. 2014; 146:700–8. e2. [PubMed: 24239563]

Figure 1. Mechanisms of AMPK activation

AMPK functions as a metabolic sensor that is activated by metabolic stress induced by hypoxia, nutrient deprivation, and drugs/compounds [e.g. biguanides, 2-deoxyglucose (2-DG)], AMP mimetic, direct AMPK activators, or reactive oxygen species (ROS). For the full activity of the kinase, a phosphorylation at the residue Thr172 in the catalytic loop is required. The main upstream kinases are the Liver kinase B1 (LKB1), the Ca²⁺/calmodulin-dependent protein kinase kinase 2 (CaMKK2), and the transforming growth factor beta-activated kinase 1 (TAK1). Uncharacterized protein phosphates (PPs) can reverse this phosphorylation.

Figure 2. AMPK-mediated metabolic and signaling reprogramming

Once activated, AMPK switches off anabolic pathways while turning on catabolic pathways to restore energy homeostasis. Thus, AMPK controls pathways involved in metabolism, cell growth, and survival. Red lines indicate direct activation, whereas inhibition is depicted in blue. A question mark indicates that it is not yet certain that the protein is directly phosphorylated. Abbreviations: ACC1/ACC2, acetyl-CoA carboxylases 1/2; HMGR, HMG-CoA reductase; SREBP, sterol response element binding protein; CHREBP, carbohydrate response element binding protein; FAO, fatty acid oxidation; TIF-1A, transcription initiation factor-1A; mTORC1, mammalian target of rapamycin complex 1; TSC2, tuberous sclerosis complex 2; GLUT1/4, glucose transporter 1, 4; PFKFB2/3, 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatases 2 and 3; TBC1D1, TBC1 domain protein-1; SIRT1, sirtuin 1; PGC-1 α , PPAR γ -coactivator-1 α ; ULK1, Unc51-like kinase-1, AMOTL1, angiomin like 1; YAP, Yes-associated protein 1.

Figure 3. Main mechanisms through which AMPK can exert its double-faced role in cancer
 AMPK activation triggers cellular processes that can both suppress and promote tumor development/progression by activating different downstream pathways in a context specific manner. Abbreviations: mTORC1, mammalian target of rapamycin complex 1; HIF-1 α , hypoxia-inducible factor 1-alpha; YAP, Yes-associated protein 1; Foxo3a, forkhead box O3; AR, androgen receptor; FAO, fatty acid oxidation; ACC2, acetyl-CoA carboxylases 2; NADPH, reduced form of nicotinamide adenine dinucleotide phosphate; ROS, reactive oxygen species; ULK1, Unc51-like kinase-1.

Figure 4. AMPK functions as “conditional” tumor suppressor and “contextual” tumor promoter
 The outcome of AMPK activation in cancer is affected by the genetic context, metabolic dependency of cancer cells, and the surrounding microenvironment. Differences in the intensity/duration of AMPK activation (e.g. physiological activation vs. drug-induced supra-physiological activation) as well as in the expression/activation of specific subunits of the heterotrimer contribute to the anti- vs pro-tumorigenic role of AMPK in different cancer types.

Figure 5. Mechanisms by which biguanides are therapeutically beneficial in LKB1-positive and negative tumors

A. Metformin or phenformin activates AMPK in pre-neoplastic cells with functional LKB1/AMPK pathway, restraining their growth and proliferation and thus delaying the onset of tumorigenesis; B. Cancer cells, in which the LKB1-AMPK pathway is not functional, cannot restore biguanides-induced energy stress and they are more sensitive to cell death (biguanide paradox).

Table 1

Population-based studies of AMPK activation in tumor tissue, clinicopathologic features, and prognosis

Author, Year [ref.]	Cancer site	Country	Population	Age range, yrs	Time period of diagnosis	N cases	Median follow-up, yrs	Antibody used for AMPK activation; method	Main findings ^a		
									Overall, cancer-specific, & progression-free survival	Tumor grade & stage	Other clinicopathologic features
Park, 2009 [71]	Prostate	USA	Patients with paraffin-embedded arrayed prostate cancer specimens	NS	NS	244	NA	p-ACC (Ser79, Cell Signaling Technology); IHC	Higher p-AMPK associated with biochemical recurrence (p=0.017).	No association of p-ACC with Gleason grade (data not shown).	No association of p-AMPK with Gleason score or disease stage at time of surgery.
Tennakoon, 2013 [72]	Prostate	USA	Patients with archival tissue collected from radical prostatectomy	NS	NS	61	NS	p-AMPKα (Thr172, Santa Cruz Biotechnology); IHC		No association of p-AMPK with Gleason score or disease stage at time of surgery.	
Choudhury, 2014 [63]	Prostate	UK	Patients with paraffin-embedded arrayed prostate cancer specimens	NS	NS	213	NA	p-AMPKα (Thr172); IHC		Higher p-AMPK associated with higher Gleason score (p=0.0251).	
Hadad, 2009 [73]	Breast	Scotland	1. Patients enrolled in Adjuvant Breast Cancer (ABC) clinical trial 2. Patients with primary, previously untreated breast cancer from Tayside University Hospitals	34–76 28–89	1992–2000 1997–2002	117 237	6.1 5.0	p-AMPKα (Thr172, Cell Signaling Technology); IHC	No association of p-AMPK with overall survival (data not shown).	Higher p-AMPK associated with lower histological grade (p=0.010 and 0.021 for cohorts 1 & 2, respectively).	Higher p-AMPK associated with fewer positive axillary nodes (p=0.021 and 0.087 for cohorts 1 & 2, respectively). No association with tumor size (data not shown).
Zhang, 2014 [74]	Breast	UK	1. Discovery cohort 2. Validation cohort Both comprised of stage I–III invasive breast cancers from patients treated by wide local excision and radiotherapy	31–70 18–72	1998–2006 1986–1998	166 609	9.0 11.2	p-AMPKα (Thr172, Cell Signaling Technology); IHC	No association of p-AMPK with overall survival (data not shown).	No association of p-AMPK with tumor grade or stage (data not shown).	No association of p-AMPK with tumor size or lymph node status (data not shown).
Su, 2014 [75]	Head and neck		Patients with surgically resected squamous cell carcinoma of the head and neck	30–89	1998–2010	118		p-AMPKα (Thr172, Cell Signaling Technology); IHC	Higher p-AMPK associated with improved overall survival in univariate (p=0.018), but not multivariate (p=0.188), analyses.	Higher p-AMPK associated with lower T stage (p=0.020). No association of p-AMPK with tumor differentiation (p=0.200).	No association of p-AMPK with surgical margin status (p=0.253) or lymph node status (p=0.369).
p-ACC (Ser79, Cell Signaling Technology); IHC									Higher p-ACC associated with worse overall survival		

Author, Year [ref.]	Cancer site	Country	Population	Age range, yrs	Time period of diagnosis	N cases	Median follow-up, yrs	Antibody used for AMPK activation; method	Main findings [†]			
									Overall, cancer-specific, & progression-free survival	Tumor grade & stage	Other clinicopathologic features	
Baba, 2010 [76]	Colorectal	USA	Incident cases in Nurses' Health Study and Health Professionals Follow-up Study	59 (20%); 60–69 (42%); 70 (38%)	1976–2004	718	10.8	p-AMPKα (Thr172, Cell Signaling Technology); IHC	in univariate (p=0.021) and multivariate (p=0.018) analyses. in univariate (p=0.021) and multivariate (p=0.018) analyses.	No association of p-AMPK with cancer-specific survival (p=0.56) in all patients combined. Higher p-AMPK associated with improved cancer-specific survival among P-MAPK3/1 positive (p=0.0006), but not P-MAPK3/1 negative (p=0.45) patients.	Higher p-AMPK associated with lower tumor grade (p=0.0009). No association of p-AMPK with tumor stage (p=0.16).	No association of p-AMPK with tumor border (p=0.80).
Zulato, 2014 [77]	Colorectal	Italy	Patients with metastatic colorectal cancer treated with FOLFIRI-bevacizumab	28–74	2007–2011	48	2.0	p-AMPKα (Thr172, Cell Signaling Technology); IHC	Higher p-AMPK associated with improved overall survival (p=0.0002). No association with progression-free survival (p=0.231).			
Kang, 2012 [78]	Gastric	South Korea	Patients receiving a combination regimen of cisplatin and S-1	22–71	2006–2010	73	2.2	p-ACC (Ser79, Cell Signaling Technology); IHC	Higher p-ACC associated with improved overall survival (p=0.0007) and improved progression-free survival (p=0.011).			
	Gastric	South Korea	Patients receiving a combination regimen of cisplatin and S-1	22–71	2006–2010	73	2.2	p-AMPKα (Cell Signaling Technology); IHC	Higher p-AMPK associated with worse relapse-free survival (p=0.022). No association with overall survival (p=0.102).	No association of p-AMPK and overall pathologic stage (p=0.955), T stage (p=0.708), N stage (p=0.807), or histology (p=0.142).	No association of p-AMPK with tumor size (p=0.600)	
Kim, 2013 [79]	Gastric	South Korea	Patients who underwent surgical gastrectomy	24–85	2003–2006	621	Up to 10 yrs	p-AMPKα (Thr172, Cell Signaling Technology); IHC	Higher p-AMPK associated with improved overall survival (p=0.024) and disease-free survival (p=0.030).	Higher p-AMPK associated with lower tumor stage (p=0.000).	Higher p-AMPK associated with absence of lymph node metastasis (p=0.000).	
Zheng, 2013 [80]	Liver	China	Patients who underwent radical resection	<50 (56%); 50 (44%)	2005–2009	273	2.7	p-AMPKα (Thr172, Cell Signaling Technology); IHC	Higher p-AMPK associated with improved overall survival (p=0.00029) and longer	Higher p-AMPK associated with lower pathologic tumor stage (0.00014) and lower	Higher p-AMPK associated with complete tumor encapsulation	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author, Year [ref.]	Cancer site	Country	Population	Age range, yrs	Time period of diagnosis	N cases	Median follow- up, yrs	Antibody used for AMPK activation; method	Main findings ¹		
									Overall, cancer- specific, & progression- free survival	Tumor grade & stage	Other clinicopathologic features
William, 2011 [81]	Lung	USA	Patients who underwent surgical resection for non- small-cell lung cancer	32–90	1997–2005	463	4.1	p-AMPK α (Thr172, Cell Signaling Technology); IHC	time to recurrence (p=0.0007 time to recurrence (p=0.0007	Edmondson grade (0.00324),	(p=0.00235) and absence of distant metastasis (p=0.00281). No association of p- AMPK with tumor size (p=0.775) or multiplicity (p=0.0932).
									Higher p-AMPK associated with improved overall survival (p=0.0009) and recurrence-free survival (p=0.0007) in all patients, and in patients with adenocarcinoma (p=0.0001 and 0.001, respectively). No association of p-AMPK with overall survival (p=0.35) or recurrence-free survival (p=0.11) in patients with squamous cell carcinoma.	No association of p- AMPK with overall pathologic stage (p=0.45), T stage (p=0.61), or N stage (p=0.66).	
Zupa, 2012 [82]	Lung	Italy	Patients who underwent surgical resection for non- small-cell lung cancer	43–83	1993–2005	47	NS	p-AMPK α 1 (Ser485, Cell Signaling Technology); RPPA	Higher p-AMPK α 1 at Ser485 (prevents AMPK activation) associated with worse overall survival (p=0.0041) among 28 pathologic stage N0 patients.		
									Higher p-ACC associated with worse overall survival (p=0.0256) among 28 pathologic stage N0 patients.		
Nanjundan, 2010 [83]	Lung	USA	Patients who underwent surgical resection for non- small-cell lung cancer	48–81	NS	46	NS	p-AMPK α (Thr172, Cell Signaling Technology); RPPA	No association of p-AMPK with recurrence or survival (data not shown).		
									Higher p-ACC associated with disease recurrence (p=0.010). No association		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author, Year [ref.]	Cancer site	Country	Population	Age range, yrs	Time period of diagnosis	N cases	Median follow- up, yrs	Antibody used for AMPK activation; method	Main findings ¹		
									Overall, cancer- specific, & progression- free survival	Tumor grade & stage	Other clinicopathologic features
Li, 2014 [84]	Ovary	USA	Patients included on a commercially available ovarian cancer tissue array (OVC1021, Pantomics Inc.)	NS	NS	97	NA	p-AMPKα (Thr172, Cell Signaling Technology); IHC	with survival (data not shown). with survival (data not shown).		Higher p-AMPK associated with lower tumor stage (data not shown).
Tsavachidou-Fenner, 2010 [85]	Kidney	USA	Patients with metastatic renal cell carcinoma who underwent nephrectomy, post-treatment with bevacizumab–erlotinib or bevacizumab alone	Median: 61	NS	37	NS	p-AMPKα (Thr172, Cell Signaling Technology) ² ; RPPA	Higher p-AMPK associated with improved overall survival (p=0.0003).		
Cancer Genome Atlas Research Network, 2013 [86]	Kidney	USA	Clear cell renal cell carcinoma patients included in the publicly available TCGA database	NS	NS	411	Up to 10 yrs	p-AMPKα (Thr172); RPPA	Higher p-AMPK associated with improved overall survival (p<0.0001).		
								p-ACC (Ser79); RPPA	Higher p-ACC associated with worse overall survival (p<0.01).		

Abbreviations: CI, confidence interval; HR, hazard ratio; IHC, immunohistochemistry; NA, not applicable; NS, not specified; p-ACC, phosphorylated AMP-activated protein kinase; *P-MAPK3/1*, extracellular signal-regulated kinase (ERK1)/2; RPPA, reverse-phase protein array; TCGA, The Cancer Genome Atlas

¹ Color code: Green: improved survival or favorable clinical features associated with AMPK activation; Red: worse survival or unfavorable clinical features associated with AMPK activation; Gray: null results

²Personal communication